Group 1 - Gree Co., Ltd. plans to use no more than 6 billion yuan of idle self-owned funds for entrusted wealth management, with a validity period of one year from the date of board approval [1] - Guosheng Technology's stock will resume trading on January 12 after completing an investigation into abnormal trading, but the company expects a net loss for 2025 [2] - Dongzhu Ecology is negotiating to terminate the acquisition of control over Kairui Xingtong due to failure to reach an agreement on valuation and other commercial terms [3] Group 2 - Jiaoyun Co., Ltd. intends to swap its passenger car sales and automotive after-service assets with the cultural and tourism-related assets of its controlling shareholder, which is expected to constitute a major asset restructuring [4] - Baogang Co., Ltd. plans to adjust the related transaction price of rare earth concentrate for the first quarter of 2026 to 26,834 yuan per ton, a slight increase from the previous quarter [5] - Luzhou Laojiao proposes a cash dividend of 13.58 yuan per 10 shares, totaling approximately 2 billion yuan [6] Group 3 - Zhenlei Technology states that the commercial aerospace industry is still in its early industrialization stage, with unpredictable contributions to revenue from batch launches [7][8] - China First Heavy Industries has only undertaken a small number of projects related to "controlled nuclear fusion," and these products have not yet generated revenue [9] - Huanxu Electronics plans to invest 30 million yuan in a private equity fund focused on AI-driven new generation information technology industries [10] Group 4 - Ruina Intelligent plans to invest approximately 169.9 million yuan to build a modern intelligent high-efficiency heat pump R&D and production base [11] - Hualan Biological intends to acquire a 35% stake in Ningbo Guangfeng Capsule Co., Ltd. for 8.4647 million yuan, with plans for further acquisitions in the future [12] - Yili Media reports that its main business and business model have not undergone significant changes, and its operations are normal [13] Group 5 - Jushi Chemical received a notice of administrative penalty for inflating revenue and profits through false trading, with a proposed fine of 2.4 million yuan [14] - Haiyou New Materials has been designated as a supplier for a well-known automotive glass manufacturer to develop and supply PDLC dimming film products [15][16] - Shanda Electric signed a strategic cooperation agreement with Shandong Development New Energy Co., Ltd. to promote the technological upgrade and large-scale development of the new energy industry in Shandong Province [17] Group 6 - China Shipbuilding Defense expects a net profit increase of 149.61% to 196.88% for 2025, driven by improved ship product revenue and production efficiency [18] - Daotong Technology anticipates a net profit increase of 40.42% to 45.1% for 2025, fueled by AI-driven services [19] - Zhenhua New Materials expects a net loss of 400 million to 500 million yuan for 2025 due to declining market demand for existing products [20] Group 7 - Greenland Holdings anticipates a net loss of 16 billion to 19 billion yuan for 2025, primarily due to declining asset prices and increased financial expenses [21] - Electric Wind Power expects a net loss of 890 million to 1.09 billion yuan for 2025, attributed to intensified competition and delays in project construction [22] - Jintou City Development forecasts a net loss for 2025 [23] Group 8 - Dazhi expects a net loss for 2025 [25] - Wantong Development anticipates a net loss for 2025 [26] - Wanfu Biological projects a net profit decline of 87.71% to 91.81% for 2025 due to market price reductions and increased R&D expenses [27] Group 9 - Zhongkong Technology expects a net profit decline of 53.07% to 61.85% for 2025, driven by economic slowdown and reduced customer demand [28] - Jian Kai Technology's shareholder plans to reduce holdings by up to 3% [29] - Huati Technology's actual controller plans to reduce holdings by up to 3% [30]

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

Core Viewpoint - Wanfu Biological (300482.SZ) expects a significant decline in net profit attributable to shareholders for 2025, projecting between 46 million to 69 million yuan, representing a year-on-year decrease of 91.81% to 87.71% [1] Financial Performance - The company's main business revenue has declined year-on-year, primarily due to a drop in domestic revenue influenced by changes in VAT rates and the impact of medical industry policies, which have pressured both volume and pricing [1] - The projected net profit attributable to shareholders shows a substantial decline, with a forecasted net profit excluding non-recurring gains and losses ranging from -15 million to -7.5 million yuan [1] Business Operations - The decline in net profit is attributed to several factors: 1. Decrease in gross profit margin due to terminal price reductions in the domestic market and changes in product structure [1] 2. The company has maintained high R&D and sales expenses to strengthen product competitiveness and explore new markets and applications [1] 3. The divestiture of non-core, less profitable businesses has resulted in certain impairment losses [1] International Business - Despite challenges in the domestic market, the company's overseas business has developed steadily, providing an important support point for overall sustainable growth [1]

公告称，公司主营业务收入同比下滑，主要原因是国内收入下滑。 智通财经APP讯，万孚生物(300482.SZ)披露2025 年度业绩预告，公司预计归属于上市公司股东的净利 润4600万元至6900万元，同比下降87.71%至91.81%;扣除非经常性损益后的净亏损750万元至1500万元。 ...

Core Viewpoint - The company expects a significant decline in net profit for the fiscal year 2025, projecting a range of 46 million to 69 million yuan, which represents a year-on-year decrease of 87.71% to 91.81% [1] Group 1: Financial Performance - The main business revenue has declined year-on-year, primarily due to a drop in domestic income [1] - The adjustment in the value-added tax rate has impacted revenue negatively [1] - Hospital business has been affected by medical industry policies, leading to pressure on both volume and pricing [1] Group 2: Business Segments - Despite the challenges in domestic operations, overseas business development remains robust, providing crucial support for the company's overall sustainable growth [1]

每经AI快讯，1月9日，万孚生物（300482）(300482.SZ)发布2025年度业绩预告，预计归属于上市公司 股东的净利润为4,600万元~6,900万元，比上年同期下降87.71%~91.81%。报告期内，公司主营业务收入 下滑，主要因国内收入受增值税税率调整及医疗行业政策影响，院内业务量价承压；海外市场稳健发 展，提供增长支撑。 ...

Group 1 - The core viewpoint of the article is that Wanfu Biological (300482) has established and approved a "Market Value Management System" to systematically promote market value management initiatives [1] - The company's market value management efforts focus on enhancing the competitiveness of its main business, optimizing corporate governance, and continuously improving the quality of information disclosure [1]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2026-003 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于补选公司第五届董事会独立董事和选举非独立董 事并调整董事会专门委员会委员的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）于 2026 年 1 月 6 日 召开第五届董事会第二十次会议，审议通过了《关于补选王菊芳女士为公司第 五届董事会独立董事的议案》《关于选举汪洋先生为公司第五届董事会非独立董 事的议案》及《关于调整公司董事会专门委员会组成人员的议案》，现将有关情 况公告如下： 一、关于补选公司第五届董事会独立董事的情况 董事会于近日收到独立董事段朝晖先生提交的书面辞职报告，段朝晖先生 因个人工作原因申请辞去公司第五届董事会独立董事职务，同时辞去董事会薪 酬与考核委员会主任委员、董事会战略委员会委员职务，其辞职后将不再担任 公司任何职务。段朝晖先生上述职务原定任期为自第五届董事会选举完成 ...

证券代码：300482 证券简称：万孚生物 公告编号：2026-004 广州万孚生物技术股份有限公司 关于召开 2026 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要提示： 1、本次股东会无增加、变更提案的情况。 2、本次股东会以现场投票和网络投票相结合的表决方式。 3、本次股东会未涉及变更前次股东会决议的情形。 4、中小投资者是指除上市公司董事、高级管理人员以及单独或者合计持有公 司 5%以上股份的股东以外的其他股东 一、召开会议的基本情况 1、股东会届次：2026 年第二次临时股东会 2、股东会的召集人：董事会 7、出席对象： （1）截至 2026 年 1 月 20 日下午深圳证券交易所收市时，在中国证券登记结算有限公司深圳分公 司登记在册的本公司全体股东，上述本公司全体股东均有权出席本次股东会，并可以以书面形式委托代 理人出席和参加表决，该股东代理人不必是本公司股东。 （2）本公司董事和高级管理人员。 （3）本公司聘请的律师及其他相关人员。 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股票上 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 第五届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 三、审议通过《关于调整公司董事会专门委员会组成人员的议案》 广州万孚生物技术股份有限公司（以下简称"公司"或"本公司"）第五届 董事会第二十次会议(以下简称"本次会议")于 2026 年 1 月 6 日下午 15:00 在 公司会议室以现场与通讯相结合的方式召开，因情况紧急，为保证董事会工作 的顺利衔接和平稳运行，本次会议经全体董事一致同意豁免会议通知时限要求， 会议通知于同日以电话、口头等方式送达全体董事。会议应到董事 8 名，实到 8 名，出席会议人数符合《公司法》和《公司章程》规定。会议由公司董事长 王继华女士主持。 经与会董事认真审议，本次会议通过以下议案： 一、审议通过《关于补选王菊芳女士为公司第五届董事会独立董事的议案》 为完善公司治理结构，保证公司董事 ...